Destiny Pharma plc (“Destiny Pharma” or “the Company”) Brighton, United Kingdom – 6 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), announces that Sir Nigel Rudd is stepping down as Chairman and a member of […]
23 Aug 2018 San Mateo, CA – August 23, 2018: Adherium (ASX:ADR) a digital health platform focused on improving medication adherence and patient outcomes, and Vitalus Health, a leading provider of comprehensive health and wellness solutions that focus on pulmonary disease management, today announced a broadened strategic program encompassing Adherium’s Hailie™ solution. With the expansion of its […]
Valencia, Calif., USA, and Melbourne, Australia, 23 August 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced the successful completion of multiple production runs for the RECELL Device® within its newly acquired manufacturing facility in Ventura, California. Effective July 1, 2018 AVITA Medical acquired the facility from a Fortune 500 manufacturer that had previously […]
Results from two U.S. pivotal trials featured in plenary session at U.S. Defense Department Military Health System Research Symposium Valencia, Calif., USA, and Melbourne, Australia, 22 August 2018 AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that results from two U.S. pivotal clinical trials demonstrating the effectiveness and clinical benefits of the RECELL® Autologous Cell Harvesting […]
Company update: Global Kinetics Corporation hits significant clinical milestones on its trajectory to revolutionise the treatment of Parkinson’s disease Leading digital health company Global Kinetics’ ground-breaking PKGTM technology recommended by world leading Parkinson’s experts ahead of achieving a key milestone on the path to USA reimbursement PORTSMOUTH, NH USA, LONDON, UK, and MELBOURNE, Australia, August […]
21 August 2018 – Asthma and Respiratory Foundation NZ announces today that it has agreed to work with Adherium to improve outcomes for asthma patients, with a special focus on New Zealand children and teenagers, in a collaboration to be known as the Kiwi Kids Program. Adherium is an an award-winning digital health company that improves medication […]
13 Aug 2018 San Mateo, CA – August 13th, 2018: Adherium (ASX: ADR), a leading digital health platform that focuses on improving medication adherence and patient outcomes, today officially launched the Hailie™ solution in the U.S., following its recent Food and Drug Administration (FDA) 510(k) over-the-counter clearance to enable sales direct to consumers. The Hailie solution […]
FDA approves expansion of program to include up to 108 patients and 26 U.S. burn centers Valencia, Calif., USA, and Melbourne, Australia, 9 August 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number of patients who may be […]
26 Jul 2018 San Mateo, CA – July 26, 2018: Adherium (ASX: ADR), an award-winning digital health platform that improves medication adherence, patient outcomes and engagement, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for over-the-counter (OTC) sales of its Hailie™ sensor for use with ProAir® HFA, Ventolin® HFA and Flovent® […]
Positive data supports product opportunities for XF-73 in dermal infection indications Data also supports planned Phase 2 clinical trial of XF-73 nasal gel for the prevention of post-surgical infection Brighton, United Kingdom – 26 July 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the […]